2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11D.10 A Phase II Trial of Tiragolumab with Carboplatin, Pemetrexed, And Atezolizumab in Non-Squamous NSCLC and Brain Metastases

P4.11D.10 A Phase II Trial of Tiragolumab with Carboplatin, Pemetrexed, And Atezolizumab in Non-Squamous NSCLC and Brain Metastases

Back to course

Pdf Summary

This document details a Phase II clinical trial exploring the combination of tiragolumab and atezolizumab in treating patients with non-small cell lung cancer (NSCLC) and brain metastases. The trial aims to determine the effectiveness of this treatment regimen, particularly its ability to reduce the need for salvage radiation therapy to the central nervous system (CNS) within 18 weeks. It involves 35 patients and considers a treatment effective if this need is at or below 27%. Secondary objectives include assessing the frequency of CNS-related adverse events, response rates of brain metastasis, overall response rates, progression-free survival, overall survival, and progression-free survival post-salvage radiotherapy.<br /><br />Patients enrolled must have confirmed NSCLC with a PD-L1 tumor proportion score (TPS) of at least 50% and untreated, evaluable brain metastases of 5 mm or more. They should display adequate organ function and an ECOG performance status of 0 or 1. Conversely, individuals requiring brain metastasis-related CNS radiation within two weeks of treatment or those on substantial steroid or anti-epileptic treatment for the same duration before treatment are excluded. Additionally, patients with tumors demonstrating specific oncogenic drivers addressed by first-line therapies are also ineligible.<br /><br />The background section references previous studies including CITYSCAPE and SKYSCRAPER-06, which assessed the combination of tiragolumab and atezolizumab in various settings, revealing mixed outcomes. The investigative team behind the trial includes several oncologists and researchers, with the trial taking place at UPMC Hillman Cancer Center in Pittsburgh, PA. The trial is an effort to address a gap in treatment for NSCLC patients with active brain metastases, a group often excluded from immunotherapy trials.

Asset Subtitle

Benjamin Schluger

Meta Tag

Speaker Benjamin Schluger

Topic Metastatic NSCLC – Immunotherapy

Keywords

Phase II clinical trial

tiragolumab

atezolizumab

non-small cell lung cancer

brain metastases

salvage radiation therapy

CNS-related adverse events

PD-L1 tumor proportion score

UPMC Hillman Cancer Center

immunotherapy trials